Metropolitan Life Insurance Company (MetLife)’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-1,561
| Closed | -$159K | – | 2468 |
|
|
2023
Q2 | $159K | Buy |
1,561
+66
| +4% | +$6.25K | 0.01% | 782 |
|
|
2023
Q1 | $136K | Sell |
1,495
-290
| -16% | -$17K | 0.01% | 842 |
|
|
2022
Q4 | $67.8K | Hold |
1,785
| – | – | ﹤0.01% | 1288 |
|
|
2022
Q3 | $44.9K | Hold |
1,785
| – | – | ﹤0.01% | 1533 |
|
|
2022
Q2 | $54.2K | Hold |
1,785
| – | – | ﹤0.01% | 1450 |
|
|
2022
Q1 | $58.5K | Sell |
1,785
-5,754
| -76% | -$171K | ﹤0.01% | 1510 |
|
|
2021
Q4 | $199K | Hold |
7,539
| – | – | ﹤0.01% | 2032 |
|
|
2021
Q3 | $758K | Buy |
7,539
+8
| +0.1% | +$938 | 0.01% | 1161 |
|
|
2021
Q2 | $1.07M | Buy |
7,531
+5,775
| +329% | +$652K | 0.02% | 965 |
|
|
2021
Q1 | $175K | Buy |
1,756
+74
| +4% | +$8.63K | ﹤0.01% | 2114 |
|
|
2020
Q4 | $208K | Sell |
1,682
-33
| -2% | -$4.34K | ﹤0.01% | 1913 |
|
|
2020
Q3 | $167K | Sell |
1,715
-21
| -1% | -$2.62K | ﹤0.01% | 1898 |
|
|
2020
Q2 | $271K | Sell |
1,736
-5,144
| -75% | -$782K | ﹤0.01% | 1612 |
|
|
2020
Q1 | $993K | Buy |
6,880
+72
| +1% | +$13.9K | 0.02% | 684 |
|
|
2019
Q4 | $1.39M | Buy |
6,808
+209
| +3% | +$38.1K | 0.02% | 727 |
|
|
2019
Q3 | $530K | Buy |
6,599
+419
| +7% | +$35.6K | 0.01% | 1253 |
|
|
2019
Q2 | $583K | Buy |
6,180
+109
| +2% | +$9.41K | 0.01% | 1213 |
|
|
2019
Q1 | $519K | Hold |
6,071
| – | – | 0.01% | 1271 |
|
|
2018
Q4 | $341K | Hold |
6,071
| – | – | 0.01% | 1471 |
|
|
2018
Q3 | $496K | Buy |
6,071
+611
| +11% | +$43.1K | 0.01% | 1354 |
|
|
2018
Q2 | $191K | Buy |
5,460
+1,897
| +53% | +$57.8K | ﹤0.01% | 1972 |
|
|
2018
Q1 | $73.1K | Hold |
3,563
| – | – | ﹤0.01% | 2407 |
|
|
2017
Q4 | $101K | Sell |
3,563
-2,929
| -45% | -$81.7K | ﹤0.01% | 2306 |
|
|
2017
Q3 | $202K | Hold |
6,492
| – | – | ﹤0.01% | 2265 |
|
|
2017
Q2 | $205K | Buy |
+6,492
| New | +$160K | ﹤0.01% | 2326 |
|
Other funds holding RETA
Metropolitan Life Insurance Company (MetLife)'s RETA Position: Q3 2023 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 1,561 shares — an estimated $159K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in RETA in Q2 2017 and held it in 25 quarters. The position peaked at $1.39M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 1,561 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $159K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2017 and held it in 25 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.39M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2023, filed 14 Nov 2023.